E-mail us
Amorphous Solid Dispersions

Amorphous solid dispersions have been shown to alter the properties of an API, including solubility, dissolution, and bioavailability. A variety of polymers or additives are available, and screening is needed to find possible miscible dispersions that will have the properties needed for development. Our service including:


The amorphous solid dispersion will then be used in simple formulations for early development (such as suspensions, drug in capsules, or preliminary formulations) or formulated into a drug product (such as tablets or capsules) for late-stage development and marketed products.


We perform comprehensive amorphous solid dispersion screening to identify ASD formulation that can provide sufficient solubility and drug release rate. Our capabilities include making mg quantity material for early development up to kilogram scale for late-stage studies to support different needs.

Resources of Amorphous Solid Dispersion

Leave a Message

Related Updates in Crystal Pharmatech

Contact Us
bd_global@crystalpharmatech.com +1-609-604-8303
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
6800 Kitimat Rd, Unit 1, Mississauga, Ontario, Canada L5N 5M1
Suite B4-101, Biobay, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, China, 215123
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
bd_global@crystalpharmatech.com +1-609-604-8303